Abstract Theincreasingincidenceofmultidrug-resistant (MDR)Pseudomonasaeruginosaisaworldwideproblem,particularlyamong critically ill patients. Since it is not anticipated that any new treatments will be available inthe nearfeature, our researchaimsto assess theefficacyandsafetyofcolistininthetreatmentofinfectionscausedbyP.aeruginosainneutropenicleukemiapatients. Astudy wasconducted at two hospitals (i.e., Beit-Jala Hospital/Bethlehem; n 78 and Augusta Victoria Hospital/Jerusalem; n 61)overaperiodof18months. Using a confidence interval of 95%, a margin of error of 5%, and a response rate of 50%, demographic andclinical characteristics were analyzed. One of the major results of our study was that colistin-treated patients had a favorable clinical response at day six and less nephrotoxicity outcomes compared to the control group. Data analyses revealed a high incidence (50–63%; n 79) of leukemia in both hospital groups. Microbiologic response, infection-related mortality, and relapse rates were not statistically significant between both groups. Our study demonstrated that colistin is highly useful and effective in the treatment of MDR P. aeruginosa in blood cancer patients. Colistin has proven superior to control group in terms of clinical response at day six. Our study has also shown lower nephrotoxicity rates, which is further encouraging and could support the potential of using colistin as an alternative therapy for such infections. As multidrug resistance continues to be a worldwide concern, the need for effective therapies such as colistin remains of great importance

Title

Arabian Journal for Science and Engineering

Publisher

springer

Publisher Country

Germany

Publication Type

Both (Printed and Online)

Volume

--

Year

2024

Pages

--